Navigation Links
Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Date:12/9/2008

al Targets of Proteasome Inhibitors Bortezomib and Carfilzomib (Abstract #2657) and The Selective Proteasome Inhibitor Carfilzomib is Well Tolerated in Experimental Animals with Dose Intensive Administration (Abstract #2765).

Carfilzomib acts by inhibiting the proteasome with a high degree of selectivity and is structurally and mechanistically distinct from bortezomib. Preclinical studies designed to assess and compare the off-target activity of bortezomib and carfilzomib indicate that carfilzomib has minimal activity on proteases other than the proteasome. In contrast, bortezomib targets several serine proteases including Cathepsin G, an enzyme whose inhibition may play a role in neuropathic pain. Proteolix researchers believe that these observations may translate into a different and possibly superior safety profile for carfilzomib as compared to bortezomib. In support of this notion, chronic administration of carfilzomib is well tolerated in rats and monkeys with no signs of the significant behavioral and histological neurotoxicities that have been described for bortezomib.

About Multiple Myeloma

According to the American Cancer Society, in 2008, approximately 19,900 new cases of multiple myeloma will be diagnosed in the United States. Newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond to treatment, most eventually relapse and require subsequent treatment. Few patients are ultimately cured of their disease.

About Carfilzomib

Carfilzomib is the first in a new class of highly specific proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic and solid
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... -- China Cord Blood Corporation (NYSE: CO ) ("CCBC" ... cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem ... company catering to the mother and child segment, today announced that ... PRC, Singapore , Hong Kong ... the Philippines and Malaysia ...
(Date:7/23/2014)... 2014 With the ability to record continuously ... more than 15 minutes, Fastec Imaging has brought the same ... speed imaging. “Finally, a high speed camera that can be ... our everyday lives.” proclaims Matt Kearney, VP of Sales for ... to demystify and simplify the traditionally complicated workflow of a ...
(Date:7/23/2014)... OncLive® is pleased to announce ... its Strategic Alliance Partnership program. , By ... Lineberger will have the opportunity to work with ... cutting-edge research initiatives, community-directed cancer prevention programs, and ... with OncLive to educate their peers by providing ...
Breaking Biology Technology:Sofinnova Raises $500 Million Biotech Venture Fund 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... Target Underlying Defect in Cystic Fibrosis; CFTR ... ... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it ... covering compounds demonstrated to improve cystic,fibrosis transmembrane conductance regulator (CFTR) ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... will begin,immediately. Fentanyl Transdermal System is ... in 25, 50, 75 and 100 mcg/hour ...
... HUNTSVILLE, Ala., Aug. 22 DNA2.0,Inc. ... synthetic genes, and,Operon Biotechnologies (http://www.operon.com ), ... formation of a partnership to utilize their,synergistic ... Operon,s oligonucleotide production platform with DNA2.0,s,gene synthesis ...
Cached Biology Technology:BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 2BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 3BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 4Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2
(Date:7/23/2014)... are crucial for providing essential fatty acids and ... feeding. There has been concern that soybean-based emulsions ... due to its composition. Combination lipid emulsions based ... have been developed to address this concern. , ... that concern may be unwarranted, according to a ...
(Date:7/22/2014)... of both still images and video of artistic ... Forty-four still images were chosen from more than ... and alumni representing more than 25 different University ... 50 submissions. , Zach Donnell, a graduate student ... organizers, noted that the exhibit highlights the interplay ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2014. Revenue ... increase of 53% compared to $4.4 million in the same ... the second quarter of 2014 was $1.4 million compared to ... in revenue and operating income was driven by higher sales ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... years ago Mark Kay, MD, PhD, published the first ... RNA interference was an effective gene-therapy technique in mice. ... flurry amongst both academic and industry research groups. , ... way, Kay's initial excitement is proving to be on ...
... phones excite the brain cortex adjacent to it, ... other neurological conditions. This finding is published in ... & Sons. The article is also available online ... million people in the world use cell phones ...
... as Ritalin to quell symptoms of attention deficit hyperactivity ... drugs work in the brain. , But new work ... clear up some of the mystery. Writing in the ... primarily target the prefrontal cortex (PFC), a region of ...
Cached Biology News:For Stanford scientists, RNAi gene therapy takes two steps forward, one step back 2Cell phone emissions excite the brain cortex 2Study reveals how ADHD drugs work in brain 2Study reveals how ADHD drugs work in brain 3
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... pending) was developed using a protein engineering approach ... binding pocket of wild-type DNase I. These changes ... DNA. The result is a versatile enzyme that ... an ability to maintain at least 50% of ...
Rabbit polyclonal to hnRNP-U...
... formation of a phosphodiester bonds between adjacent ... DNA molecules or between oligonucleotides which are ... 45 - 65?. Tfi DNA Ligase is ... than conventional DNA ligases, Thus, Tfi DNA ...
Biology Products: